Drug Profile
Research programme: CD27 agonists - Apogenix
Alternative Names: HERA-CD27-ligand; HERA-CD27LLatest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Apogenix
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action CD27 antigen stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 25 Aug 2023 CD27 agonists are still in preclinical trials for Solid tumours in Germany (Apogenix pipeline, August 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Solid-tumours in Germany
- 06 Sep 2017 Preclinical data in Solid tumours presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2017)